• Lunit will present two AI-powered pathology studies on ovarian and bladder cancers Nov. 7 at SITC 2026 in Phoenix.
• The Labcorp collaboration found higher tumor cell proliferation in ovarian cancers with homologous recombination deficiency than in those without it.
• The CellCarta study linked greater immune infiltration and closer tumor–T cell proximity to atezolizumab response in muscle-invasive bladder cancer.
• The bladder cancer findings suggest spatial immune patterns could help identify predictive biomarkers, but require further investigation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunit Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88717) on November 04, 2026, and is solely responsible for the information contained therein.